目的 探究采用痫愈胶囊联合丙戊酸镁治疗癫痫患者的临床效果。方法 选取响水县人民医院2014年1月-2016年12月收治的81例癫痫患者为研究对象，随机分成对照组（40例）和治疗组（41例）。对照组患者口服丙戊酸镁缓释片，1片/次，2次/d。治疗组患者在对照组基础上口服痫愈胶囊，5片/次，3次/d。两组患者均连续治疗2个月。观察两组患者临床疗效，比较治疗前后两组患者癫痫发作次数、ADL评分、药物保留率和不良反应。结果 治疗后，对照组和治疗组临床总有效率分别为82.50%和97.56%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的癫痫发作次数明显降低，ADL评分均明显升高，同组比较差异具有统计学意义（P<0.05）；且治疗组患者癫痫发作次数和ADL评分均要明显优于对照组患者（P<0.05）。治疗24、36周后，治疗组药物保留率分别80.88%和60.29%，均明显高于对照组62.69%、40.30%，两组比较差异具有统计学意义（P<0.05）。治疗期间，对照组不良反应发生率为22.50%，显著高于治疗组的4.88%，两组比较差异具有统计学意义（P<0.05）。结论 痫愈胶囊联合丙戊酸镁治疗癫痫患者具有显著的临床疗效，且安全性好，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Xianyu Capsules combined with magnesium valproate in treatment of epilepsy. Methods Patients (81 cases) with epilepsy in Xiangshui People's Hospital from January 2014 to December 2016 were randomly divided into control (40 cases) and treatment (41 cases). Patients in the control group were po administered with Magnesium Valproate Sustained Release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Xianyu Capsules on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the seizure frequency and ADL score, the drug retention rate and adverse events in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.50% and 97.56% respectively, and there were differences between two groups (P < 0.05). After treatment, the seizure frequency in two groups was significantly decreased, but ADL score was significantly increased, and the difference was statistically significant in the same group (P < 0.05), and the seizure frequency and ADL score in the treatment group were significantly better than those in the control group (P < 0.05). After treatment for 24 and 36 weeks, the drug retention rate in the treatment group was 80.88% and 60.29%, which was significantly higher than 62.69% and 40.30% in the control group, respectively, and there were differences between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 22.50%, which was significantly higher than 4.88% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Xianyu Capsules combined with magnesium valproate has significant clinical efficacy in treatment of epilepsy with high safety, which has a certain clinical application value.